Based on these findings, we hypothesized that expression of C1q genes (i.e., C1QA, C1QB, and C1QC) may be associated with the efficacy of HER2+ subtype BC patients receiving HER2-targeted therapy. This evidence concerns the gene C1QB and breast cancer.